• Male or Female at least 18 years of age, and provide informed consent prior to study procedures.

• Have moderate to severe HS classified as Hurley stage II or III for at least 6 months refractory to conventional therapies with a total AN count of greater than or equal to 5 prior to enrollment/randomization

• Failed at least 1 course of oral antibiotics for treatment of HS (or demonstrated intolerance to, or had a contraindication to oral antibiotics for treatment of their HS).

• Women of Childbearing potential must have a urine pregnancy test at screening, wk 0 and prior to administration of the study medication

• Women of childbearing potential must be willing to continue a highly effective method of birth control throughout the study (oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal foam/gel/film/cream/suppository (if available in their locale); male partner sterilization (the vasectomized partner should be the sole partner for that participant); true abstinence (when this is in line with the preferred and usual lifestyle of the participant).

• Negative screening for tuberculosis (TB) (Quantiferon Gold, T-spot) within 3 months prior to screening

• If a positive history of latent tuberculosis:

‣ Currently receiving treatment for latent TB per standard of care

⁃ Have documentation of having completed treatment within 5 years prior to baseline

• Agree not to have a live vaccination during the study.